Results: Baseline corticosteroid use was comparable between groups (belimumab, 481 [%]; placebo, 241 [%]), with most patients receiving > mg/day (%). A numerically greater proportion of patients with baseline dose > mg/day in the belimumab group had a dose reduction of ≥25% to ≤ mg/day during Weeks 40–52 compared with patients receiving placebo (belimumab, %; placebo, %; OR [95% CI] [, ]; p=). Fewer patients in the belimumab group versus the placebo group required ≥50% increase (min ≥5 mg/day) in dose during Weeks 40–52 (Week 52: belimumab, %; placebo, %; OR [95% CI] [, ]; p=) or any increase in corticosteroid from Weeks 20–28 and 36–52 (Week 52: belimumab, %; placebo, %; OR [95% CI] [, ]; p=). The percentage of patients with ≥50% reduction in corticosteroid dose by Week 52 was similar in the belimumab (range: –%) and placebo (range: 0–%) groups. A small number of patients in each group required an increase (≥50%, min ≥5 mg/day) in dose from baseline (range: belimumab –%; placebo, –%). Mean (SD) cumulative corticosteroid dose at Week 52 was mg () in the belimumab group and mg () in the placebo group; the median (IQR) was the same in both groups ( [1825–5475]; p=). Median (IQR) corticosteroid dose at baseline was 10 mg/day (IQR 5–15) in both groups; no meaningful change occurred in either group by Week 52. Mean dose at baseline was mg/day and mg/day in the belimumab and placebo groups, with mean changes at Week 52 of - mg and - mg, respectively. Adverse events incidence (≥1) was similar (belimumab, %; placebo %).
Register for alerts
If you have registered for alerts, you should use your registered email address as your username